158 related articles for article (PubMed ID: 31955309)
1. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Gabizon AA; Tahover E; Golan T; Geva R; Perets R; Amitay Y; Shmeeda H; Ohana P
Invest New Drugs; 2020 Oct; 38(5):1411-1420. PubMed ID: 31955309
[TBL] [Abstract][Full Text] [Related]
2. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Gabizon A; Shmeeda H; Tahover E; Kornev G; Patil Y; Amitay Y; Ohana P; Sapir E; Zalipsky S
Adv Drug Deliv Rev; 2020; 154-155():13-26. PubMed ID: 32777239
[TBL] [Abstract][Full Text] [Related]
3. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Golan T; Grenader T; Ohana P; Amitay Y; Shmeeda H; La-Beck NM; Tahover E; Berger R; Gabizon AA
Cancer Med; 2015 Oct; 4(10):1472-83. PubMed ID: 26172205
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
[TBL] [Abstract][Full Text] [Related]
7. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Sapir E; Pfeffer R; Wygoda M; Purim O; Levy A; Corn B; Amitay Y; Ohana P; Gabizon A
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):64-73. PubMed ID: 36933845
[TBL] [Abstract][Full Text] [Related]
9. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
[No Abstract] [Full Text] [Related]
10. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.
Wei X; Patil Y; Ohana P; Amitay Y; Shmeeda H; Gabizon A; Barenholz Y
Mol Pharm; 2017 Dec; 14(12):4339-4345. PubMed ID: 28045540
[TBL] [Abstract][Full Text] [Related]
11. Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.
Dorot S; Tankel J; Doviner V; Shmeeda H; Amitay Y; Ohana P; Dagan A; Ben-Haim M; Reissman P; Gabizon A
Cancer Chemother Pharmacol; 2022 Aug; 90(2):109-114. PubMed ID: 35802145
[TBL] [Abstract][Full Text] [Related]
12. Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.
Fang YP; Hu PY; Huang YB
Drug Des Devel Ther; 2018; 12():159-169. PubMed ID: 29391780
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X; Warner SB; Wagner KT; Caster JM; Zhang T; Ohana P; Gabizon AA; Wang AZ
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):547-55. PubMed ID: 27681751
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres.
Rump AF; Woschée U; Theisohn M; Fischbach R; Heindel W; Lackner K; Klaus W
Eur J Clin Pharmacol; 2002 Oct; 58(7):459-65. PubMed ID: 12389068
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
van Ruth S; Mathôt RA; Sparidans RW; Beijnen JH; Verwaal VJ; Zoetmulder FA
Clin Pharmacokinet; 2004; 43(2):131-43. PubMed ID: 14748621
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of intraarterial mitomycin C in the chemoembolisation treatment of liver metastases.
Rump AF; Botvinik-Helling S; Theisohn M; Biederbick W; Schierholz JM; Stemmler M; Fischbach R; Heindel W; Lackner K; Klaus W
Gen Pharmacol; 1996 Jun; 27(4):669-71. PubMed ID: 8853303
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer.
Guadagni S; Aigner KR; Palumbo G; Cantore M; Fiorentini G; Pozone T; Deraco M; Clerico M; Chaudhuri PK
J Clin Pharmacol; 1998 Oct; 38(10):936-44. PubMed ID: 9807975
[TBL] [Abstract][Full Text] [Related]
18. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Van der Speeten K; Stuart OA; Chang D; Mahteme H; Sugarbaker PH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):147-56. PubMed ID: 20857115
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
Anderson N; Lokich J; Moore C; Bern M; Coco F
Cancer Invest; 1999; 17(8):586-93. PubMed ID: 10592766
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.
Zalipsky S; Saad M; Kiwan R; Ber E; Yu N; Minko T
J Drug Target; 2007; 15(7-8):518-30. PubMed ID: 17671898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
